Merck to close 8 research sites and 8 manufacturing sites

In Chinese, the number 8 is considered a lucky number. Today, Merck announced that they'll be phasing out operations at eight research sites and eight manufacturing sites. They will also continue to consolidate office facilities worldwide, as part of the global Merck and Schering-Plough merger restructuring program.

Here are some interesting snippets from the press release today:

As part of today's announcement, Merck plans to phase out operations at eight research sites over the next two years. These sites include: Montreal, Canada; Boxmeer (Nobilon facility only), Oss, and Schaijk, Netherlands; Odense, Denmark; Waltrop, Germany; Newhouse, Scotland; and Cambridge (Kendall Square), Massachusetts, U.S.

Beginning in the second half of 2010, the company will phase out operations at eight manufacturing facilities and these sites will exit the global network as activities are transferred to other locations. Specifically, the company intends to cease manufacturing activities at its facilities in Comazzo, Italy; Cacem, Portugal; Azcapotzalco, Mexico; Coyoacan, Mexico, and Santo Amaro, Brazil, and intends to sell the Mirador, Argentina and Miami Lakes, Florida, facilities. In Singapore, chemical manufacturing will be phased out at the legacy Merck site, but it will continue at the legacy Schering-Plough site. The company's extensive pharmaceutical manufacturing operations will continue at these two Singapore facilities.

Don't miss this:

Merck continues to expect its total workforce to be reduced by approximately 15 percent across all areas of the combined company worldwide as part of the initial phases of its merger restructuring program. The company said it will continue to hire new employees in strategic growth areas of the business as necessary.

The Health Industry and the Stock Market

So much is changing in the healthcare industry. Have you spoken with your stock broker? If you're like me, then you probably try to do everything online. I'm a big fan of Online Trading. Why? Because it's so convenient and you can easily make changes easily by getting on a computer and logging in to your favorite Online Broker. It's easy for me since I'm always carring some type of computer around (usually an ultra-mobile PC that is connected to the Internet). The Internet has simplified so many things, including Stock Trading. It's hard to imagine what the world was like before we had the World Wide Web.

Who do you use to trade Stocks, Options, Mutual Funds, ETFs and Fixed Incomes? Pharmaceutical companies are merging, others are downsizing to reduce costs. Pfizer is merging with Wyeth. Schering-Plough is merging with Merck. Roche is aquiring Genentech. This may not be the best time to leave a job in clinical medicine to join the folks in pharma. With all these mergers and acquisitions, Stock Trading must be going crazy these days. The stock market has been in a downhill tumble and no one seems to know what's going to happen in the market. There is so much uncertainly about the current economy. What services or tools do you use for Online Trading?

Merck, Schering-Plough, and now J&J/Centocor

The Merck/Schering-Plough merger/reverse acquisition may hit some problems according to some because of J&J/Centocor and the co-marketing of Remicade (infliximab). Golimumab is a similar biologic agent that is currently in development. It is supposed to be co-marketed with Schering-Plough, but I guess we're not sure what's going to happen if Merck and Schering-Plough join forces. All these pharma merges/acquisitions are starting to get pretty crazy. Some are forecasting that thousands of jobs may get cut, but no one seems to be sure where those cuts may occur. I guess we'll just have to wait and see what happens here. These are some incredibly dramatic times in the pharma industry.

Merck to Acquire Schering-Plough

It looks like Merck will be acquiring Schering-Plough in a $41.1 billion deal. But wait, it's a bit confusing. People are referring to this as a "reverse merger" and Merck's top executive, Chairman and CEO Richard Clarke, will lead the combined company, but Schering-Plough will be the surviving public corporation. The new company will be called Merck.